Criteria for the clinical use of Intravenous Immunoglobulin in Australia - Second Edition

Contents

Bibliography

General references

Biotext 2004, A systematic literature review and report on the efficacy of intravenous immunoglobulin therapy and its risks, commissioned by the National Blood Authority on behalf of all Australian Governments. Available from: http://www.nba.gov.au/pubs/pdf/report-lit-rev.pdf.

Blood and Blood Products Committee 2000, Review of the use and supply of intravenous immunoglobulins in Australia. A report by the Blood and Blood Products Committee (prepared under the auspice of the Australian Health Ministers’ Advisory Council, Canberra), Blood and Blood Products Committee, Canberra.

Commonwealth of Australia 2003, National Blood Authority Act 2003, no. 29, an act to enhance the management of Australia’s blood supply, and for related purposes, Australian Government, Canberra. Available from: http://www.comlaw.gov.au/Details/C2012C00338

Flood, P, Wills, P, Lawler, P, et al 2006, Review of Australia’s plasma fractionation arrangements, Australian Government, Canberra. Available from: http://www.health.gov.au/19 - Haemophilia Foundation ACT.pdf

Frommer, MS & Madronio, C 2006, The use of intravenous immunoglobulin in Australia. A report for the National Blood Authority, Sydney Health Projects Group, University of Sydney, Sydney.

National Blood Authority 2003, National blood agreement between the Commonwealth of Australia and the states and territories, Australian Government, Canberra. Available from: http://www.nba.gov.au/policy/agreement.html

National Blood Authority 2005, Intravenous immunoglobulin: development, dissemination and implementation of clinical use guidelines, discussion paper, Australian Government, Canberra.

National Blood Authority 2006, The supply and use of plasma products in Australia, Australian Government, Canberra. Available from: http://www.nba.gov.au/pubs/pdf/plasma-use-au.pdf

Orange, JS, Hossny, EM, Weiler, CR, et al 2006, ‘Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology’, Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. S525–53. (Note erratum in Journal of Allergy and Clinical Immunology, vol. 117, no. 6, p. 1483; dosage error in text).